Ophthalmic gene therapy company Horama has announced an exclusive licensing agreement for global rights to a program targeting retinal dystrophy associated with pathogenic CRB1 gene mutations.
The company, which is focused on gene therapies for rare ophthalmic diseases, has signed the agreement with the Leiden University Medical Center (LUMC), in Netherlands.
Horama will receive an exclusive worldwide license to certain patent rights and expertise for the drug candidate, known as HORA-001.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze